ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0

作者：

Chung, Carmen ^{[1
]}

Jiang, Haiyan ^{[2
]}

Isaranuwatchai, Wanrudee

Di Maio, Mas-Simo ^{[3
]}

Lau, Anthea ^{[2
]}

Hoch, Jeffrey

Feld, Ronald ^{[2
]}

Tsao, Ming-Sound ^{[4
]}

Gridelli, Cesare ^{[5
]}

Gallo, Ciro ^{[6
]}

Ciardiello, Fortunato ^{[6
]}

Butts, Charles A. ^{[7
]}

Perrone, Francesco ^{[3
]}

Leighl, Natasha B. ^{[8
]}

机构：

[1] Univ Toronto, Toronto, ON M5S 1A1, Canada

[2] Univ Hlth Network, Toronto, ON, Canada

[3] Natl Canc Inst, Milan, Italy

[4] Princess Margaret Hosp, Toronto, ON, Canada

[5] Sg Moscati Hosp, Avellino, Italy

[6] Univ Naples 2, Naples, Italy

[7] Cross Canc Inst, Edmonton, AB, Canada

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

cisplatin and gemcitabine; erlotinib; advanced non-small cell lung cancer; economic analysis;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.11-020

引用

页码：S602 / S603

页数：2

共 50 条

[21] Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC)
Stinchcombe, T.
Bradford, D. S.
Lee, C. B.
Moore, D. T.
Bakri, K. M.
Taylor, M. A.
Crane, J. M.
Schwartz, G.
Hensing, T. A.
Socinski, M. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Han, B.
Chu, T.
Zhong, R.
Zhong, H.
Zhang, B.
Zhang, W.
Shi, C.
Qian, J.
Han, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
[23] Gemcitabine and cisplatin in advanced non small cell lung cancer (NSCLC)
Garcia-Gomez, R
Lopez-Criado, P
Guevara, S
Lahoz, C
Chaib, C
Gonzalez, C
Santiago, J
De Alvaro, J
Carrion, R
Perez-Manga, G
ANNALS OF ONCOLOGY, 1998, 9 : 93 - 94
[24] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
Gaspar, E.
Firvida, J.
Amenedo, M.
Orts, D.
Salgado, M.
LLorca, C.
Ramos, M.
Perez, E.
Cervera, J.
Abal, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer
Hsiao, Shih-Chuan
Su, Wu-Chou
NATIONAL MEDICAL JOURNAL OF INDIA, 2009, 22 (02): : 67 - 69
[26] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Merimsky, O.
Cheng, A. C.
Reck, M.
Au, S. K.
von Pawel, J.
ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
[27] Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study
Lu, You
Huang, Meijuan
Fan, Qingxia
Wu, Qi
Wang, Jin
Li, Lu
Zhang, Xi
Guo, Chengye
Li, Wenhui
Peng, Feng
Ouyang, Xuenong
Yu, Ding
Cai, Xiaohong
Xu, Yong
Hou, Mei
Luo, Rongcheng
Zhang, Tao
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[28] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
Merimsky, Ofer
Cheng, Chi-Kin
Au, Joseph Siu-Kie
Von Pawel, Joachim
Reck, Martin
ONCOLOGY REPORTS, 2012, 28 (02) : 721 - 727
[29] Meta-analysis of pemetrexed (P) plus gemcitabine (G) in first-line, advanced (adv) non-small cell lung cancer (NSCLC)
Ye, Z.
Treat, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[30] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): AN ECONOMIC ANALYSIS
Spigel, David
Harwin, William
Dranitsaris, George
Binder, Gary
Weber, Paul
Renschler, Markus F.
Socinski, Mark A.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1176 - S1177

← 1 2 3 4 5 →